Skip to content

Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines

Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines: Multicenter, Randomized Controlled Trial (NUTRIREA-2)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01802099
Acronym
NUTRIREA2
Enrollment
2410
Registered
2013-03-01
Start date
2013-03-01
Completion date
2015-09-01
Last updated
2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure, Shock

Keywords

mechanical ventilation, early enteral nutrition, intensive care unit, early parenteral nutrition, critical care medicine, nosocomial infection, mortality, shock, vasoactive drug

Brief summary

The purpose of this study is to assess the hypothesis that, as compared to early intravenous feeding, early nutrition via the enteral route is associated with reduced Day 28-mortality in critically ill patients treated with mechanical ventilation and vasoactive drug.

Interventions

OTHEREnteral nutrition
OTHERParenteral nutrition

Sponsors

Centre Hospitalier Departemental Vendee
Lead SponsorOTHER
Ministry of Health, France
CollaboratorOTHER_GOV
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University Hospital, Tours
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Invasive mechanical ventilation expected to be required more than 48 hours * Nutrition started within 24 hours after initiation of endotracheal mechanical ventilation * Treatment with vasoactive drug administered via a central venous catheter * Age over 18 years * Signed information

Exclusion criteria

* Abdominal surgery within 1 month before inclusion * History of esophageal, gastric, duodenal or pancreatic surgery * Bleeding from the esophagus, stomach or bowel * enteral nutrition via gastrostomy or jejunostomy * pregnancy * Treatment-limitation decisions * Current inclusion in a trial on comparison between enteral and parenteral nutrition

Design outcomes

Primary

MeasureTime frame
Mortality28 days

Secondary

MeasureTime frameDescription
Acute Bowel Ischemia Rateuntil weaning of mechanical ventilation (average: 7 days)
Vomiting Rateuntil weaning of mechanical ventilation (average: 7 days)
Mortality Rate90 days
Ventilator-associated Pneumonia Rateuntil weaning of mechanical ventilation (average: 7 days)
Nosocomial Infections Rateuntil discharge from ICU (average: 10 days)Bloodstream infection Urinary tract infection Catheter-related infection Other infections
Length of Stay in Intensive Care Unit (ICU)until discharge from ICU (average: 10 days)
Length of Stay in Hospitaluntil discharge from hospital (average: 17 days)
Variations in Sepsis-related Organ Failure Assessment (SOFA) Scorefirst week (7 days) of mechanical ventilation
Calories Intakeuntil weaning of mechanical ventilation (average : 7 days)
Proportion of Patients Given 100% of the Calorie Targetuntil weaning of mechanical ventilation (average: 7 days)
Cumulative Calorie Deficit From Day 0 to Day 7During the first week (7 days) of mechanical ventilation
Intensive Care Unit (ICU) Mortality Rateuntil discharge from ICU (average: 10 days)
Hospital Mortality RateUntil discharge from hospital (average : 17 days)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJean Reignier, MD, PhD

CHD Vendee

Baseline characteristics

Characteristic
Age, Continuous66 years
STANDARD_DEVIATION 14
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
France
1202 participants
Sex: Female, Male
Female
1624 Participants
Sex: Female, Male
Male
393 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
other
Total, other adverse events
0 / 1,2080 / 1,202
serious
Total, serious adverse events
0 / 1,2080 / 1,202

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 5, 2026